ArticleJournal of endocrinological investigation2026
Assessment of mitochondrial peptide humanin in women with polycystic ovary syndrome: serum and skeletal muscle profile.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeHumanin is a mitochondria-derived peptide (MDP) secreted in response to oxidative stress and linked to diverse cellular processes including inflammation and insulin resistance (IR). In a PCOS rat model, humanin has been shown to be downregulated in polycystic ovaries, and exogenous humanin supplementation has attenuated IR and ovarian morphological abnormalities. We aimed to investigate the role of humanin in the pathophysiology of PCOS by comparing serum and skeletal muscle tissue profiles in women with PCOS and healthy women.
methodsForty women with PCOS [(mean ± SD) age:21.8 ± 2.3 years, BMI:25.0 ± 4.8 kg/m2] and 40 age- and BMI-matched healthy controls were included. Anthropometric, hormonal, biochemical measurements and body composition analyses were carried out in all participants. Vastus lateralis muscle biopsies were analyzed for humanin expression from a subset of patients and controls who consented to the procedure.
resultsSerum humanin levels were significantly lower in the PCOS group than those in controls [Median (IQR):474.9 (313.0–633.5) pg/mL vs. 672.3 (481.7-764.6) pg/mL p < 0.001)]. Western blot analysis showed no significant difference in skeletal muscle humanin levels between PCOS and control groups (p = 0.71). Serum humanin showed negative correlations with testosterone, 2 h insulin during OGTT, total cholesterol, LDL, and triglycerides.
conclusionSerum humanin levels are decreased in PCOS suggesting mitochondrial dysfunction that appears to be associated with androgen excess, IR and lipids. Reduction of circulating humanin is unlikely to be linked to an alteration of this MDP in the skeletal muscle which constitutes the majority of the mitochondrial reserve in the body.
Indexed as
Identifiers
41186863What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.